

CURRICULUM VITAE

Name and Surname: RAMAZAN COŞAR
Academic Title: Assistant Professor
Work Address:
Email: ramazan.cosar@afsu.edu.tr

Degree	Department/Program	University	Year
Sub-Specialty in Medicine	DAHİLİ TIP BİLİMLERİ BÖLÜMÜ	Erciyes University	2022
Medical Specialty	DAHİLİ TIP BİLİMLERİ BÖLÜMÜ	Kırıkkale University	2016
Bachelor's Degree	TIP PR.	Mersin University	2010
Bachelor's Degree	ASKERİ TIP PR. (ERKEK)	Gülhane Military Medical Academy	2008

PUBLICATIONS**A. Articles published in international peer-reviewed journals:**

- A1.** Nuransoy Cengiz A., Bozkurt O., Cengiz M., Özkan M., İnanç M., Kefeli U., Çabuk D., Erman M., Kılıçkap S., Köşeci T. vd., "Prognostic Significance of C-PLAN Index in Patients Treated with Immunotherapy for Non-Small-Cell Lung Cancer", *Journal of Clinical Medicine*, vol. 15, 2026.
- A2.** Türkel A., Deliktaş Onur İ., Karakayalı A., Bıyıklı Alemdar M., Aygör Kabasakal E., Alkan A., Yıldız S., Majidova N., Emin G., Gürbüz A. F. vd., "Survival outcomes and recurrence patterns of early-stage HER2-positive breast cancer patients on adjuvant T-DM1 treatment: Turkish Oncology Group (TOG) Study", *Clinical Breast Cancer*, 2025.
- A3.** Buğday İ., İnanç M., Özkan M., Bozkurt O., Coşar R., Fırat S. T., Mutlu E., Eser M., Dişli A. K., Cengiz M., "Prognostic role of prognostic nutritional index change in patients with extensive stage small cell lung cancer treated with platinum-based chemotherapy", *BMC Cancer*, vol. 25, no. 1, 2025.
- A4.** Buğday İ., İnanç M., Özkan M., Bozkurt O., Coşar R., Fırat S. T., Mutlu Özkan E., Eser M., Dişli A. K., Cengiz M., "Prognostic Factors in Metastatic Urothelial Carcinoma Treated Without Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (M-VAC): A Single-Center Retrospective Study", *Cureus*, 2025.
- A5.** Yıldırım Keskin G. S., Yetginoğlu Ö., Vurğun S., Güzel E. Z., Özkan F. E., Yılmaz M., Söylemez C. M., Ağyol Y., Akbaş S., Sağıroğlu M. F. vd., "Survival Outcomes in Metastatic Germ Cell Tumors: A Multicenter Study from Turkey", *Medicina (Lithuania)*, vol. 61, no. 6, pp. 1-13, 2025.
- A6.** Buğday I., İnanç M., Özkan M., Bozkurt O., Coşar R., Fırat S. T., Mutlu E., Eser M., Dişli A. K., Cengiz M., "Prognostic impact of elevated C-reactive protein and procalcitonin in patients with extensive-stage small cell lung cancer", *Anti-Cancer Drugs*, vol. 36, no. 2, pp. 135-139, 2025.
- A7.** Bozkurt O., Türkmen U., Deniz K., Fırat S. T., Coşar R., Doğan E., İnanç M., Özkan M., "Prognostic Significance of Glyoxalase-1 Enzyme Activity in Metastatic Pancreatic Cancer Patients", *UHOD - Uluslararası Hematoloji-Onkoloji Dergisi*, vol. 35, no. 2, pp. 86-94, 2025.
- A8.** Mutlu E., Özkan M., Fırat S. T., Coşar R., "Response and Tolerability of Palbociclib Plus Fulvestrant in Breast Cancer Patient with Bone Marrow Metastasis and Cytopenia: A Case Report", *ERCIYES MEDICAL JOURNAL*, vol. 45, no. 1, pp. 101-103, 2023.
- A9.** Doğan E., Fırat S. T., Coşar R., Bozkurt O., İnanç M., Özkan M., "Efficacy of second-line targeted agents in kras wild metastatic colorectal cancer patients who received prior targeted agent: First anti-epidermal growth factor receptor or vascular endothelial growth factor in right and left colon?", *Journal of Oncology Pharmacy Practice*, vol. 26, no. 4, pp. 781-786, 2020.

A10. Bozkurt O., Doğan E., Fırat S. T., Coşar R., İnanç M., Ertürk Zararsız G., Metin Ö., "Role of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Predictors Before Treatment for Metastatic Bladder Cancer Patients Receiving First-Line Chemotherapy", *ERCIYES MEDICAL JOURNAL*, vol. 41, no. 3, pp. 255-260, 2019.

A11. Demirci H., Coşar R., Çiftçi Ö., Kalan Sarı I., "Atypical diabetic ketoacidosis: Case report", *Balkan Medical Journal*, vol. 32, no. 1, pp. 124-126, 2015.

C. National/international books written or chapters in books:

C2. Chapters in national/international books written:

C2.1. Coşar R., "Adjuvant Treatment Approaches for Operated Rectal Cancer", *CURRENT TREATMENTS FOR COLORECTAL CANCER*, Türkiye Klinikleri Tıp Bilimleri Dergisi, 2025.

C2.2. Coşar R., "Anaplastik Tiroid Kanseri", *NADİR TÜMÖRLER*, Akademisyen Kitabevi A.Ş., 2022.

C2.3. Coşar R., "Foliküler Tiroid Kanseri Medikal Tedavisi", *ENDOKRİN SİSTEM TÜMÖRLERİ*, Akademisyen Kitabevi A.Ş., 2021.

C2.4. Coşar R., "COVID-19 Pandemisinde Geriatrik Onkoloji Hastalarının Yönetimi", *COVID-19 VE KANSER*, Akademisyen Kitabevi A.Ş., 2021.

D. Articles published in national peer-reviewed journals:

D1. Mutlu Özkan E., Fırat S. T., İnanç M., Coşar R., Buğday İ., Doğan E., Gündoğan E., "Prognostic value of nutrition and inflammation based scores in patients with metastatic pancreatic cancer", *Anatolian Current Medical Journal*, vol. 8, 2026.

D2. Mutlu E., Bozkurt O., İnanç M., Özkan M., Fırat S. T., Coşar R., Buğday İ., Cengiz M., Dişli A. K., Eser M., "The effect of albumin to alkaline phosphatase ratio on survival in patients with metastatic bone sarcomas", *Hitit Medical Journal*, vol. 6, 2024.

D3. Mutlu E., Bozkurt O., İnanç M., Özkan M., Fırat S. T., Coşar R., Buğday İ., Cengiz M., Dişli A. K., Eser M., "The effect of albumin to alkaline phosphatase ratio on survival in patients with metastatic bone sarcomas", *Hitit Medical Journal*, 2024.

D4. Kalan Sarı I., Coşar R., Durmaz Ceylan Ş., "Hypercalcemia due to Primary Hyperparathyroidism in a Patient with Graves' Disease", *The Journal of Kırıkkale University Faculty of Medicine*, vol. 24, no. 1, pp. 192-196, 2022.

D5. Mutlu E., Fırat S. T., İnanç M., Bozkurt O., Coşar R., Özkan M., "Risk factors for 30-day mortality in patients with cancer and COVID-19 in Turkey: A single center retrospective study", *Annals of Medical Research*, vol. 29, no. 2, pp. 93-98, 2022.

D6. Coşar R., Yalçın S., Çifci A., Durmaz Ceylan Ş., Güngüneş A., "Meme kanseri subgruplarının sıklığı ve otoimmün tiroid hastalığının prognoz üzerine etkisi", *Journal of Medicine and Palliative Care*, vol. 2, no. 4, pp. 105-112, 2021.

D7. Bozkurt O., Fırat S. T., Doğan E., Coşar R., İnanç M., Özkan M., "The impact of systemic inflammatory markers on survival in metastatic gastric cancer patients receiving first-line chemotherapy", *Annals of Medical Research*, vol. 26, 2019.